Valuation: Alector, Inc.

Market Cap 18Cr 16Cr 15Cr 13Cr 25Cr 1.72TCr 26Cr 171.75Cr 67Cr 852.81Cr 68Cr 66Cr 2.87TCr P/E 2026 *
-1.89x
P/E 2027 * -2.53x
Enterprise Value -6.73Cr -5.84Cr -5.43Cr -5Cr -9.43Cr -642.24Cr -9.6Cr -64Cr -25Cr -318.97Cr -25Cr -25Cr -1.07TCr EV / Sales 2026 *
-9.81x
EV / Sales 2027 * -6.4x
Free-Float
86.82%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Alector, Inc.

1 day+6.58%
1 week+8.72%
Current month-19.40%
1 month-19.40%
3 months-31.65%
6 months-14.29%
Current year+3.85%
1 week 1.47
Extreme 1.47
1.67
1 month 1.37
Extreme 1.37
2.14
Current year 1.37
Extreme 1.37
2.74
1 year 1.09
Extreme 1.09
3.4
3 years 0.87
Extreme 0.87
9.06
5 years 0.87
Extreme 0.87
29.3
10 years 0.87
Extreme 0.87
43.32
Manager TitleAgeSince
Chief Executive Officer 71 01/05/2013
Director of Finance/CFO 52 20/06/2025
Chief Tech/Sci/R&D Officer - 01/01/2017
Director TitleAgeSince
Director/Board Member 71 01/05/2013
Director/Board Member 72 01/10/2018
Chairman 77 13/06/2023
Date Insider Type Main position Quantity % Market Cap.
09/07/26 Free

Controller/Auditor

20,000 0.0180%
26/02/26 Sell

Controller/Auditor

4,079 0.0037%
05/12/25 Sell

Controller/Auditor

4,753 0.0044%
Change 5-day change 1-year change 3-year change Capi.($)
+6.58%+8.72%+1.25%-74.57% 18Cr
-0.81%-0.33%+27.15%+81.12% 5.52TCr
+2.33%-5.02%+28.53%+67.18% 5.38TCr
-0.11%+0.86%-15.63%-13.56% 2.35TCr
-1.58%-5.51%-3.51%+375.36% 2.2TCr
+2.49%-0.92%+20.31%-12.15% 1.98TCr
+0.11%-1.73%+28.42%-33.76% 1.74TCr
+0.58%-5.88%+16.30%+540.37% 1.47TCr
+1.16%+0.58%+51.87%+181.96% 1.41TCr
-5.09%-10.87%+153.11%+272.20% 1.3TCr
Average +0.57%-1.46%+30.78%+138.42% 2.34TCr
Weighted average by Cap. +0.23%-0.44%+27.60%+125.05%

Financials

2026 *2027 *
Net sales 68.57L 59.56L 55.31L 51.01L 96.08L 65Cr 97.82L 6.55Cr 2.56Cr 33Cr 2.57Cr 2.52Cr 109.33Cr 2.29Cr 1.99Cr 1.85Cr 1.7Cr 3.21Cr 218.45Cr 3.26Cr 22Cr 8.56Cr 108.49Cr 8.59Cr 8.4Cr 364.85Cr
Net income -9.41Cr -8.17Cr -7.59Cr -7Cr -13Cr -898.46Cr -13Cr -90Cr -35Cr -446.22Cr -35Cr -35Cr -1.5TCr -9.66Cr -8.39Cr -7.79Cr -7.19Cr -14Cr -922.37Cr -14Cr -92Cr -36Cr -458.1Cr -36Cr -35Cr -1.54TCr
Net Debt -25Cr -21Cr -20Cr -18Cr -35Cr -2.36TCr -35Cr -235.99Cr -92Cr -1.17TCr -93Cr -91Cr -3.94TCr -33Cr -28Cr -26Cr -24Cr -46Cr -3.12TCr -47Cr -311.66Cr -122.03Cr -1.55TCr -122.56Cr -119.88Cr -5.2TCr
Logo Alector, Inc.
Alector, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. It also develops alector brain carrier (ABC), a proprietary blood-brain barrier platform, which is applied to its next-generation product candidates and research pipeline. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration. Its clinical development portfolio includes latozinemab (AL001) and AL101/GSK4527226, while its preclinical and research pipeline candidates include ADP037-ABC, ADP050-ABC, ADP056, and ADP063-ABC/ADP064-ABC. Its first product candidate, latozinemab, is a human recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of FTD-GRN patients. The AL101/GSK4527226, is a human recombinant monoclonal antibody designed to elevate PGRN levels in the brain.
Employees
103
Date Price Change Volume
30/26/30 $1.620 +6.58% 4,53,153
29/26/29 $1.520 0.00% 3,07,858
28/26/28 $1.520 +0.66% 3,42,803
27/26/27 $1.510 +2.03% 2,29,001
24/26/24 $1.480 -0.67% 3,25,295
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
1.620USD
Average target price
3.100USD
Spread / Average Target
+91.36%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALEC Stock